Publications

The Utility of Urinalysis in Determining the Risk of Renal Relapse in ANCA-Associated Vasculitis.
Clin J Am Soc Nephrol 2018 Feb 25;13(2):251-257. Epub 2018 Jan 25.
Due to the number of contributing authors, the affiliations are provided in the Supplemental Material.



Proteomic Analysis of Sera from Individuals with Diffuse Cutaneous Systemic Sclerosis Reveals a Multianalyte Signature Associated with Clinical Improvement during Imatinib Mesylate Treatment.
J Rheumatol 2017 May 15;44(5):631-638. Epub 2017 Mar 15.
From the Division of Immunology and Rheumatology, Stanford University School of Medicine; Institute for Immunity, Transplantation and Infection, Stanford University School of Medicine, Stanford; Department of Rheumatology, Palo Alto VA Health Care System, Palo Alto, California; Department of Rheumatology, Hospital for Special Surgery, New York, New York, USA.

Integrated, multicohort analysis of systemic sclerosis identifies robust transcriptional signature of disease severity.
JCI Insight 2016 Dec 22;1(21):e89073. Epub 2016 Dec 22.
Institute for Immunity, Transplantation, and Infection,; Division of Biomedical Informatics Research, Department of Medicine, Stanford University, California, USA.








Allosteric modulation of proteinase 3 activity by anti-neutrophil cytoplasmic antibodies in granulomatosis with polyangiitis.
J Autoimmun 2015 May 3;59:43-52. Epub 2015 Mar 3.
Comprehensive Pneumology Center, Institute of Lung Biology and Disease (iLBD), University Hospital, Ludwig Maximilians University and Helmholtz Zentrum München, Member of the German Center of Lung Research, Max-Lebsche-Platz 31, 81377 Munich, Germany; Max Planck Institute of Neurobiology, Planegg-Martinsried, Germany. Electronic address:

Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement.
J Am Soc Nephrol 2015 Apr 7;26(4):976-85. Epub 2014 Nov 7.
Division of Pulmonary and Critical Care Medicine and Division of Nephrology and Hypertension, Mayo Clinic College of Medicine, Rochester, Minnesota;

A large-scale genetic analysis reveals a strong contribution of the HLA class II region to giant cell arteritis susceptibility.
Am J Hum Genet 2015 Apr 26;96(4):565-80. Epub 2015 Mar 26.
Instituto de Parasitología y Biomedicina "López-Neyra," CSIC, PTS Granada, Granada 18016, Spain.

Increased rho kinase activity in temporal artery biopsies from patients with giant cell arteritis.
Rheumatology (Oxford) 2015 Mar 10;54(3):554-8. Epub 2014 Sep 10.
Department of Rheumatology, Hospital for Special Surgery, Department of Medicine, Weill-Cornell Medical College, Autoimmunity and Inflammation Program, Hospital for Special Surgery and Department of Clinical Pathology and Laboratory Medicine, Weill-Cornell Medical College, New York, NY, USA. Department of Rheumatology, Hospital for Special Surgery, Department of Medicine, Weill-Cornell Medical College, Autoimmunity and Inflammation Program, Hospital for Special Surgery and Department of Clinical Pathology and Laboratory Medicine, Weill-Cornell Medical College, New York, NY, USA.




















Domains of health-related quality of life important to patients with giant cell arteritis.
Arthritis Rheum 2003 Dec;49(6):819-25
Johns Hopkins University School of Medicine, Hopkins Bayview Medical Center, 4940 Eastern Avenue, Baltimore, MD 21224, USA.



The Recurrence of Digital Ulcers in Patients with Systemic Sclerosis after Discontinuation of Oral Treprostinil.
J Rheumatol 2016 09 15;43(9):1665-71. Epub 2016 Jun 15.
From the Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland; University of Michigan, Ann Arbor, Michigan; Cleveland Clinic, Cleveland, Ohio; Medical College of Wisconsin, Milwaukee, Wisconsin; University of Utah, Salt Lake City, Utah; New York University (NYU) Langone Medical Center, Lake Success; Hospital for Special Surgery, New York, New York; Benaroya Research Institute at Virginia Mason, Seattle, Washington; Georgetown University, Washington, DC; University of North Carolina at Chapel Hill, Chapel Hill; United Therapeutics Corporation, Research Triangle Park, North Carolina, USA.A.A. Shah, MD, MHS, Assistant Professor of Medicine, Director of Clinical and Translational Research, Johns Hopkins Scleroderma Center, Division of Rheumatology, Johns Hopkins University School of Medicine; E. Schiopu, MD, Assistant Professor of Internal Medicine, University of Michigan; S. Chatterjee, MD, Associate Professor of Medicine, Cleveland Clinic; M.E. Csuka, MD, Professor of Medicine, Medical College of Wisconsin; T. Frech, MD, Associate Professor of Medicine, University of Utah; A. Goldberg, MD, Clinical Assistant Professor, NYU Langone Medical Center; R. Spiera, MD, Professor of Clinical Medicine, Hospital for Special Surgery; S.L. Peng, MD, PhD, Vice President, Clinical Development, Benaroya Research Institute at Virginia Mason; R.J. McBride, DrPH, Student, University of North Carolina at Chapel Hill; J.M. Cleveland, MS, Director, Biostatistics, United Therapeutics Corp.; V. Steen, MD, Professor of Medicine, Georgetown University.







Trial of Tocilizumab in Giant-Cell Arteritis.
N Engl J Med 2017 07;377(4):317-328
From the Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston (J.H.S., S.H.U.); Roche Products, Welwyn Garden City (K.T., S.D., N.C.), and Southend University Hospital NHS Foundation Trust, Westcliff-on-Sea (B.D.) - both in the United Kingdom; Genentech, South San Francisco, CA (M.K.); the Department of Rheumatology, Medicine III, University Medical Center and Faculty of Medicine Technische Universität Dresden, Dresden (M.A.), Friedrich-Alexander-University Erlangen-Nürnberg, Department of Internal Medicine 3-Rheumatology and Immunology (J.R.), and Institute of Clinical Immunology (G.S.), Universitätsklinikum Erlangen, Erlangen, and the Division of Rheumatology and Clinical Immunology, Department of Medicine IV, University of Munich, Munich (H.S.-K.) - all in Germany; the Department of General Internal Medicine, University Hospitals Gasthuisberg, Leuven, Belgium (D.B.); the Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center, Groningen, the Netherlands (E.B.); the Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona (M.C.C.); the Division of Internal Medicine, Azienda Ospedaliera-Istituto di Ricovero e Cura a Carattere Scientifico di Reggio Emilia and Università di Modena e Reggio Emilia, Reggio Emilia, Italy (C.S.); and Hospital for Special Surgery, New York (R.S.).


OF